The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists
The effective control of Diabetes Mellitus (DM) is an actual problem from optimal expenditures of health care system point of view. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are one of the modern options for glycemia control in DM Type 2 and included in all current guidelines for the trea...
Saved in:
Main Authors: | S. K. Zyryanov (Author), I. N. Dyakov (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
by: I. N. Dyakov, et al.
Published: (2021) -
Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017) -
Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective
by: Nimer S. Alkhatib, et al.
Published: (2022) -
Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery
by: R. R. C. New, et al.
Published: (2024) -
Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
by: Laurie L. Baggio, et al.
Published: (2021)